Form 4: Catalyst Pharmaceuticals CEO Richard Daly Reports Stock Transactions
SEC Form 4
Richard Daly, CEO of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On December 27, 2024, Richard Daly, the President and CEO of Catalyst Pharmaceuticals, had 1,333 restricted stock units vest, which converted into common stock.
- The company withheld 324 shares to satisfy tax obligations related to the vesting.
- Following these transactions, Daly directly owns 235,833 shares of Catalyst Pharmaceuticals common stock.
- He also holds 2,280,858 restricted stock units.
- The restricted stock units vest in three equal tranches annually on December 27, 2023, December 27, 2024, and December 27, 2025.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation and tax procedures. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.
Key Dates
| Date | Description |
|---|---|
| 12/27/2023 | First tranche vesting date for restricted stock units (1/3rd). |
| 12/27/2024 | Second tranche vesting date for restricted stock units (1/3rd); stock transaction date. |
| 12/27/2025 | Third tranche vesting date for restricted stock units (1/3rd). |
| 12/31/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.